Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data.

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY

Przegla̜d Gastroenterologiczny Pub Date : 2022-01-01 Epub Date: 2022-01-23 DOI:10.5114/pg.2022.112777

Joaquim Prado P Moraes-Filho, Gerson Domingues, Décio Chinzon, Juliana Leite Soares Guedes, Cláudia Yang Santos, Schlioma Zaterka

{"title":"Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data.","authors":"Joaquim Prado P Moraes-Filho, Gerson Domingues, Décio Chinzon, Juliana Leite Soares Guedes, Cláudia Yang Santos, Schlioma Zaterka","doi":"10.5114/pg.2022.112777","DOIUrl":null,"url":null,"abstract":"Introduction: Although potassium-competitive acid blockers (P-CABs) prompted safety concerns when first developed, they ultimately proved to have a favourable safety profile.Aim: To assess the safety of vonoprazan in the management of gastroesophageal reflux disease (GERD), peptic ulcers, or gastroduodenal mucosal lesions induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).Material and methods: From March to June 2021, a literature search was conducted using Medline via PubMed, Cochrane library, Lilacs, SciELO, and Centre for Reviews and Dissemination (CRD) electronic databases. After applying the eligibility criteria, 10 studies were included in this review. Of these 10 articles, vonoprazan was used as initial therapy in 6 and as maintenance therapy in 4. Adverse event rates were similar for vonoprazan and proton-pump inhibitors (PPIs).Conclusions: Our findings suggest that vonoprazan is a safe option for the management of erosive oesophagitis, gastric/peptic ulcers, or peptic ulcers induced by chronic use of aspirin or NSAIDs.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"17 4","pages":"266-273"},"PeriodicalIF":1.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/e1/PG-17-46211.PMC9743326.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2022.112777","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Although potassium-competitive acid blockers (P-CABs) prompted safety concerns when first developed, they ultimately proved to have a favourable safety profile.

Aim: To assess the safety of vonoprazan in the management of gastroesophageal reflux disease (GERD), peptic ulcers, or gastroduodenal mucosal lesions induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).

Material and methods: From March to June 2021, a literature search was conducted using Medline via PubMed, Cochrane library, Lilacs, SciELO, and Centre for Reviews and Dissemination (CRD) electronic databases. After applying the eligibility criteria, 10 studies were included in this review. Of these 10 articles, vonoprazan was used as initial therapy in 6 and as maintenance therapy in 4. Adverse event rates were similar for vonoprazan and proton-pump inhibitors (PPIs).

Conclusions: Our findings suggest that vonoprazan is a safe option for the management of erosive oesophagitis, gastric/peptic ulcers, or peptic ulcers induced by chronic use of aspirin or NSAIDs.

Abstract Image

查看原文本刊更多论文

治疗胃/消化性溃疡的沃诺普拉赞：安全性数据的系统回顾。

简介：目的：评估vonoprazan治疗长期服用阿司匹林或非类固醇抗炎药（NSAIDs）引起的胃食管反流病（GERD）、消化性溃疡或胃十二指肠粘膜病变的安全性：2021年3月至6月，通过PubMed、Cochrane图书馆、Lilacs、SciELO和CRD电子数据库的Medline进行了文献检索。根据资格标准，本综述共纳入 10 项研究。在这 10 篇文章中，有 6 篇文章将 Vonoprazan 用作初始疗法，有 4 篇文章将其用作维持疗法。Vonoprazan 和质子泵抑制剂（PPIs）的不良事件发生率相似：我们的研究结果表明，vonoprazan 是治疗侵蚀性食管炎、胃/消化性溃疡或长期服用阿司匹林或非甾体抗炎药引起的消化性溃疡的安全选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.